Hendricks PS

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

Simonsson O, Bradley M, Black JC +3

Politically Salient Events May Modulate Effects of Naturalistic Psychedelic Use on Support for Partisan Violence.

Simonsson O, Hendricks PS, Osika W +1

PreprintLSD

Child and maternal health outcomes following antenatal exposure to classic psychedelic substances: a systematic review

Sun S, Hanson C, Hendricks PS +9

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial.

Hendricks PS, Lappan SN, Shelton RC +8

Advancing the Field of Psychedelic Epidemiology.

Simonsson O, Sun S, Hendricks PS +1

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.

Johnson MW, Naudé GP, Hendricks PS +1

Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.

Carlisle NA, Simonsson O, MacCarthy S +5

Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.

Olofsson M, Osika W, Goldberg SB +6

How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.

Dourron HM, Copes H, Grossman DH +6

ArticleKetamine

Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks.

Mehtani NJ, Anderson BT, Alexander I +4

Naturalistic psychedelic use and changes in depressive symptoms.

Simonsson O, Hendricks PS, Swords CM +2

Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.

Dourron HM, Bradley M, Simonsson O +4

ArticleMDMA

A systematic review of income and education reporting in psychedelic clinical trials.

Grossman DH, Madden KM, Mehtani NJ +4

Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey.

Bahceci D, Siefried K, Steele M +9

Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.

Simonsson O, Goldberg SB, Osika W +5

Associations between psychedelic-related and meditation-related variables: A longitudinal study.

Simonsson O, Chaturvedi S, Hendricks PS +5

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

On Minimizing Risk and Harm in the Use of Psychedelics.

Evans J, Aixalà M, Anderson BT +28

ArticleLSD

Rural-urban divide in risk perception of LSD: Implications for psychedelic-assisted therapy.

Bradley M, Grossman D, Simonsson O +2

Practical considerations in the establishment of psychedelic research programs.

Barnett BS, Vest MF, Delatte MS +7

Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.

Gribben A, Burke T, Harrington C +8

ArticleMDMA

Psychedelic and MDMA-Related Adverse Effects-A Call for Action.

Simonsson O, Johnson MW, Hendricks PS

Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.

Simonsson O, Goldberg SB, Hendricks PS

Psilocybin-assisted therapy and HIV-related shame.

Mehtani NJ, Johnson MO, Hendricks PS +2

Psychedelic Microdosing among Young Adults from Southern California.

Harlow AF, Hendricks PS, Leventhal AM +1

Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.

Honk L, Stenfors CUD, Goldberg SB +6

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

O'Donnell KC, Anderson BT, Barrett FS +9

Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.

Simonsson O, Hendricks PS, Stenfors CU +3

If Everything Is Psychedelic, Then Nothing Is: A Response to O'Donnell et al. and Lepow et al.

Nichols DE, Hendricks PS, Nichols CD

ArticleDMT

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Dourron HM, Nichols CD, Simonsson O +3

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.

Yaden DB, Berghella AP, Hendricks PS +6

Psychedelic use and psychiatric risks.

Simonsson O, Goldberg SB, Chambers R +3

Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.

Simonsson O, Osika W, Stenfors CUD +3

The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers.

Hendricks PS, Nichols CD

ArticleKetamine

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.

Aday JS, Barnett BS, Grossman D +3

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.

Simonsson O, Stenfors CUD, Goldberg SB +2

Adapting psychedelic medicine for headache and chronic pain disorders.

Schindler EAD, Hendricks PS

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.

Zia FZ, Baumann MH, Belouin SJ +7

Classic psychedelic use and current meditation practice.

Simonsson C, Chambers R, Hendricks PS +6

Proposed Consensus Statement on Defining Psychedelic Drugs.

Nichols DE, Nichols CD, Hendricks PS

Past, Present, and Future of Psychedelics: A <i>Psychedelic Medicine</i> Roundtable Discussion.

Hendricks PS, Nichols CD, Cunningham KA +3

Editors' Introduction to <i>Psychedelic Medicine</i>.

Hendricks PS, Nichols CD

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.

Simonsson O, Hendricks PS, Chambers R +2

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

Kiluk BD, Kleykamp BA, Comer SD +24

Classic psychedelics, health behavior, and physical health.

Simonsson O, Hendricks PS, Chambers R +2

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.

Henningfield JE, Coe MA, Griffiths RR +10

Prevalence and associations of classic psychedelic-related seizures in a population-based sample.

Simonsson O, Goldberg SB, Chambers R +3

ArticleLSD

Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study.

Hendricks PS, Copes H, Family N +3

ArticleLSD

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.

Family N, Hendricks PS, Williams LT +4

Shedding Light on Classic Psychedelics and Self-Harm.

Grossman DH, Hendricks PS

Associations between lifetime classic psychedelic use and cardiometabolic diseases.

Simonsson O, Osika W, Carhart-Harris R +1

Europe PMC2021

Associations between lifetime classic psychedelic use and markers of physical health.

Simonsson O, Sexton JD, Hendricks PS

Europe PMC2021

Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.

Sexton JD, Nichols CD, Hendricks PS

Europe PMC2019

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Johnson MW, Hendricks PS, Barrett FS +1

Europe PMC2019

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS +1

Europe PMC2018

The relationships of classic psychedelic use with criminal behavior in the United States adult population.

Hendricks PS, Crawford MS, Cropsey KL +4

Europe PMC2018